NeuroSense Therapeutics Statistics
Total Valuation
NRSN has a market cap or net worth of $25.21 million. The enterprise value is $24.88 million.
Important Dates
The next estimated earnings date is Friday, April 4, 2025, before market open.
| Earnings Date | Apr 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NRSN has 23.13 million shares outstanding. The number of shares has increased by 42.04% in one year.
| Current Share Class | 23.13M |
| Shares Outstanding | 23.13M |
| Shares Change (YoY) | +42.04% |
| Shares Change (QoQ) | +5.88% |
| Owned by Insiders (%) | 51.29% |
| Owned by Institutions (%) | 2.96% |
| Float | 11.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | -8.95 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.21
| Current Ratio | 0.21 |
| Quick Ratio | 0.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.17 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -219.64% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 399.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$644,222 |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.44% in the last 52 weeks. The beta is 1.25, so NRSN's price volatility has been higher than the market average.
| Beta (5Y) | 1.25 |
| 52-Week Price Change | -20.44% |
| 50-Day Moving Average | 1.12 |
| 200-Day Moving Average | 1.07 |
| Relative Strength Index (RSI) | 44.12 |
| Average Volume (20 Days) | 159,318 |
Short Selling Information
The latest short interest is 161,324, so 0.70% of the outstanding shares have been sold short.
| Short Interest | 161,324 |
| Short Previous Month | 236,500 |
| Short % of Shares Out | 0.70% |
| Short % of Float | 1.43% |
| Short Ratio (days to cover) | 1.00 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.19M |
| Pretax Income | -10.11M |
| Net Income | -11.60M |
| EBITDA | -11.17M |
| EBIT | -11.19M |
| Earnings Per Share (EPS) | -$0.66 |
Full Income StatementBalance Sheet
The company has $344,000 in cash and $19,000 in debt, giving a net cash position of $325,000 or $0.01 per share.
| Cash & Cash Equivalents | 344,000 |
| Total Debt | 19,000 |
| Net Cash | 325,000 |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | -2.82M |
| Book Value Per Share | -0.14 |
| Working Capital | -3.00M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |